BioWiki

差分

この文書の現在のバージョンと選択したバージョンの差分を表示します。

この比較画面にリンクする

プロスタグランジン [2013/06/09 18:08] (現在)
ライン 1: ライン 1:
 +======プロスタグランジン======
 +[[アラキドン酸]](20個の炭素をもつ不飽和脂肪酸)からシクロオキシゲナーゼによる反応を経て得られる化合物。非常に多くの生理的な現象にかかわっている。 (MeSH: [[MeSH>​68011453]])
 +
 +=====プロスタグランジン エンドペルオキシド =====
 +[[アラキドン酸]]からプロスタグランジン群や[[トロンボキサン]]を生合成する前駆体 これらは生理学的にも活性な化合物で、血管や気道平滑筋、血小板凝集などに影響を与える。もっとも良く見られるのはプロスタグランジンH2である。
 +
 +{{pubchem>​s_template:​25245222|Prostaglandin H2}}
 +
 +Prostaglandin H2 - [[アラキドン酸]]から[[シクロオキシゲナーゼ]]による反応で得られる環状エンドペルオキシド中間体で、ここからさらに一連の酵素反応によって2種類のプロスタグランジンへ変換される。(MeSH:​ [[MeSH>​68044262]])
 +
 +===== プロスタグランジンA =====
 +
 +{{pubchem>​s_template:​5281912|PGA1}}
 +
 +{{pubchem>​s_template:​5280880|PGA2}}
 +
 +
 +
 +===== プロスタグランジンD =====
 +{{pubchem>​s_template:​448457|PGD2}}
 +===== プロスタグランジンF =====
 +
 +{{pubchem>​s_template:​5283044|6-Ketoprostaglandin F1 alpha}}
 +Epoprostenol(プロスタグランジンI)の加水分解物
 +
 +===== プロスタグランジンI =====
 +{{pubchem>​s_template:​5280427|prostaglandin I2,​Epoprostenol,​PGI2}}
 +
 +
 +===== Prostaglandins - MeSH =====
 +(temporary memo)
 +
 +  *[[mesh>​68011449|Prostaglandin Endoperoxides]]\\ Precursors in the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. They are physiologically active compounds, having effect on vascular and airway smooth muscles, platelet aggregation,​ etc. Year introduced: 1978 
 +    *[[mesh>​68011462|Prostaglandins G]]\\ A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. Most frequently encountered member of this group is the prostaglandin G2. Year introduced: 1991(1978)
 +    *[[mesh>​68011463|Prostaglandins H]]+ \\ A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin H2. Year introduced: 1991(1978)
 +  *[[mesh>​68011454|Prostaglandins A]]\\ (13E,​15S)-15-Hydroxy-9-oxoprosta-10,​13-dien-1-oic acid (PGA(1)); (5Z,​13E,​15S)-15-hydroxy-9-oxoprosta-5,​10,​13-trien-1-oic acid (PGA(2)); (5Z,​13E,​15S,​17Z)-15-hydroxy-9-oxoprosta-5,​10,​13,​17-tetraen-1-oic acid (PGA(3)). A group of naturally occurring secondary prostaglandins derived from PGE; PGA(1) and PGA(2) as well as their 19-hydroxy derivatives are found in many organs and tissues. Year introduced: 1975 
 +  *[[mesh>​68011456|Prostaglandins B]]\\ Physiologically active prostaglandins found in many tissues and organs. They are potent pressor substances and have many other physiological activities. Year introduced: 1991(1978)
 +  *[[mesh>​68011457|Prostaglandins D]]\\ Physiologically active prostaglandins found in many tissues and organs. They show pressor activity, are mediators of inflammation,​ and have potential antithrombotic effects. Year introduced: 1984(1978)
 +    *[[mesh>​68015230|Prostaglandin D2]]\\ The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor,​ platelet-activating-factor-inhibitory,​ and cytotoxic effects. Year introduced: 1989 
 +  *[[mesh>​68011458|Prostaglandins E]]\\ (11 alpha,​13E,​15S)-11,​15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,​13E,​15S)-11,​15-dihydroxy-9-oxoprosta-5,​13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,​13E,​15S,​17Z)-11,​15-dihydroxy-9-oxoprosta-5,​13,​17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. Year introduced: 1975 
 +    *[[mesh>​68015232|Dinoprostone]]\\ A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. Year introduced: 1989 
 +  *[[mesh>​68011460|Prostaglandins F]]\\ (9 alpha,11 alpha,​13E,​15S)-9,​11,​15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,​11,​alpha,​13E,​15S)-9,​11,​15-trihydroxyprosta-5,​13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,​13E,​15S,​17Z)-9,​11,​15-trihydroxyprosta-5,​13,​17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. Year introduced: 1975 
 +    *[[mesh>​68015121|6-Ketoprostaglandin F1 alpha]]\\ The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. Year introduced: 1982 
 +    *[[mesh>​68015237|Dinoprost]]\\ A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.Year introduced: 1989 
 +  *[[mesh>​68044062|Prostaglandins I]]\\ A class of cyclic prostaglandins that contain the 6,9-epoxy bond. Endogenous members of this family are biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES. Year introduced: 2004
 +    *[[mesh>​68011464|Epoprostenol]]\\ A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION,​ PULMONARY). Year introduced: 1991(1978)
 +
 +
 +
 +
 +======Links======
 +
 +
 +
 +
 +{{tag>​脂肪酸}}